Previous close | 3.1600 |
Open | 0.0000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | 425,926 |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8500 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MILAN, January 03, 2023--Newron Pharmaceuticals announces striking six-month interim results for evenamide as an add-on therapy for Treatment Resistant Schizophrenia (TRS).
MILAN, September 15, 2022--Newron Pharmaceuticals today announces its half-year 2022 financial results and operational highlights and updates its R&D and business activities.
MILAN, July 01, 2022--Newron extends Senior Management team and strengthens its commitment to ESG by appointing Filippo Moriggi as Vice President of Operations.